LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs.
LyGenesis’ technology enables one donor organ to treat dozens of patients, Instead of one donor organ treating one patient.
LyGenesis was founded in 2017 and is based in Pittsburgh, Pennsylvania.
LyGenesis uses outpatient endoscopic ultrasound for transplantation of donor cells, which engraft, proliferate, and become a functioning ectopic organ.
LyGenesis's lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration.
LyGenesis is backed by Juvenescence and Longevity Vision Fund. The company raised $4M from Debt financing round on Oct 21, 2019. This brings the total funding raised by LyGenesis is $7M to date.